{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:12:17Z","timestamp":1785726737405,"version":"3.56.0"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Chronic migraine (CM) is a debilitating neurological disorder characterized not only by persistent and severe pain, but also by substantial cognitive dysfunction that affects attention, working memory, processing speed, and executive functions. These neuropsychological disturbances are likely influenced by overall disease burden and are further modulated by affective comorbidities, sleep disturbances, and medication overuse. OnabotulinumtoxinA (BoNT-A) is an established preventive therapy for CM, supported by strong evidence of both efficacy and safety. This narrative review synthesizes findings from studies examining the relationship between BoNT-A treatment and domain-specific cognitive improvements in CM. It also outlines the potential pathophysiological mechanisms underlying these effects, summarizes the limitations of the existing literature, and highlights priorities for future research. Current evidence suggests that BoNT-A may confer neurocognitive benefits, particularly in working memory and processing speed, and that these improvements may occur partly independently of reductions in headache frequency. These favorable cognitive effects appear to be plausibly linked to decreased nociceptive \u201cnoise\u201d and improved cortical inhibition, potentially mediated through modulation of central sensitization, nociceptive signaling, and affective states.<\/jats:p>","DOI":"10.3390\/toxins18040153","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:02:49Z","timestamp":1774339369000},"page":"153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Botulinum Toxin for Chronic Migraine: Beyond Headache Reduction and Toward Possible Cognitive Benefits"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-7388","authenticated-orcid":false,"given":"Mauro","family":"Silvestrini","sequence":"first","affiliation":[{"name":"Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Viticchi","sequence":"additional","affiliation":[{"name":"Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4869-402X","authenticated-orcid":false,"given":"Sergio","family":"Salvemini","sequence":"additional","affiliation":[{"name":"Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"De Vanna","sequence":"additional","affiliation":[{"name":"Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bartolini","sequence":"additional","affiliation":[{"name":"Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3802-2320","authenticated-orcid":false,"given":"Simona","family":"Luzzi","sequence":"additional","affiliation":[{"name":"Neurological Clinic, Marche Polytechnic University, Via Conca 71, 60020 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Paracka, L., and Dressler, D. (2025). Botulinum toxin for chronic migraine. J. Neural Transm.","DOI":"10.1007\/s00702-025-03055-2"},{"key":"ref_3","unstructured":"(2025). GBD 2023 Headache Collaborators. Global, regional, and national burden of headache disorders, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023. Lancet Neurol., 24, 988\u2013989."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e027953","DOI":"10.1136\/bmjopen-2018-027953","article-title":"Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine","volume":"9","author":"Herd","year":"2019","journal-title":"BMJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Santoro, A., Fontana, A., Copetti, M., Miscio, A.M., and d\u2019Orsi, G. (2025). Real-world insights into the effectiveness and tolerability of onabotulinumtoxinA in chronic migraine: A long-term evaluation of up to 11 years. Toxins, 17.","DOI":"10.3390\/toxins17040208"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s10194-024-01923-y","article-title":"Migraine and cognitive dysfunction: A narrative review","volume":"25","author":"Fernandes","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ilgaz Aydinlar, E.I., Erdogan Soyukibar, T., and Yalinay Dikmen, P. (2024). The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1417303"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e000014","DOI":"10.1136\/bmjno-2019-000014","article-title":"Cognitive effects of onabotulinumtoxinA in chronic migraine","volume":"2","author":"Ho","year":"2020","journal-title":"BMJ Neurol. Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3331024251368328","DOI":"10.1177\/03331024251368328","article-title":"Deciphering the mechanisms: Pathophysiology of migraine related cognitive dysfunction","volume":"45","author":"Fernandes","year":"2025","journal-title":"Cephalalgia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/0004-282x20190159","article-title":"Cognitive impairment in chronic migraine: A cross sectional study in a clinic based sample","volume":"78","author":"Latysheva","year":"2020","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez Huertas, A., Camejo Mas, O., Garcia Roldan, S., Alonso-Castillo, R., Pulido-Fraiz, L., Higuera Ruiz de la Hermosa, A., Portocarrero-S\u00e1nchez, L., and D\u00edaz-de-Ter\u00e1n, J. (2025). OnabotulinumtoxinA is an effective treatment for reducing the interictal burden in patients with chronic migraine: A prospective observational study. Toxins, 17.","DOI":"10.3390\/toxins17090463"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Prudenzano, M.P. (2024). Botulinum Toxin and Migraine: Goals and Perspectives. Toxins, 16.","DOI":"10.3390\/toxins16120530"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/PRS.0000000000005111","article-title":"Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine","volume":"143","author":"Bruloy","year":"2019","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0022-3565(24)38842-1","article-title":"Cleavage of SNAP 25 by Botulinum Toxin Type A requires receptor mediated endocytosis, pH dependent translocation, and zinc","volume":"296","author":"Kalandakanond","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kumar, R., and Singh, B.R. (2025). Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020777"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Marinelli, S., Pavone, F., and Luvisetto, S. (2025). Pharmacological Interaction of Botulinum Neurotoxins with Excitatory and Inhibitory Neurotransmitter Systems Involved in the Modulation of Inflammatory Pain. Toxins, 17.","DOI":"10.3390\/toxins17080374"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41582-024-01002-5","article-title":"Insights from 25 years of onabotulinumtoxinA in migraine: Mechanisms and management","volume":"20","author":"Alpuente","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Valente, M., Lettieri, C., Russo, V., Janes, F., and Gigli, G.L. (2021). Clinical and neurophysiological effects of botulinum neurotoxin type A in chronic migraine. Toxins, 13.","DOI":"10.3390\/toxins13060392"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Reyes, N., Huang, J.J., Choudhury, A., Pondelis, N., Locatelli, E.V., Felix, E.R., Pattany, P.M., Galor, A., and Moulton, E.A. (2023). Botulinum toxin A decreases neural activity in pain related brain regions in individuals with chronic ocular pain and photophobia: An fMRI study. Front. Neurosci., 17.","DOI":"10.3389\/fnins.2023.1202341"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/s41380-024-02768-2","article-title":"Resting state functional connectivity in anxiety disorders: A multicenter fMRI study","volume":"30","author":"Langhammer","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"kkaf007","DOI":"10.1093\/psyrad\/kkaf007","article-title":"Advances in functional magnetic resonance imaging based brain function mapping: A deep learning perspective","volume":"5","author":"Zhao","year":"2025","journal-title":"Psychoradiology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Oishi, M., Sakurai, N., Kawasaki, Y., Sasaki, K., Kasai, S., and Kodama, N. (2024). Investigation of functional connectivity differences based on anxiety tendencies. Front. Behav. Neurosci., 18.","DOI":"10.3389\/fnbeh.2024.1498612"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70264","DOI":"10.1111\/jocd.70264","article-title":"The Face of Emotion: Botulinum Toxin, Emotional Anatomy, and Mood Modulation","volume":"24","author":"Vanaria","year":"2025","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gilman Kuric, T., Popovic, Z., Matosa, S., Strujic, E., Gacic, I., Mirosevic Zubonja, T., Juric, S., Pecek Prpic, M., Jelusic, V., and Biuk, D. (2026). Beyond improvement of motor symptoms: Central effects of botulinum toxin on anxiety and depression in focal dystonia, hemifacial spasm, and blepharospasm. Toxins, 18.","DOI":"10.3390\/toxins18020062"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, Y., Liu, T., and Luo, W. (2021). Botulinum neurotoxin therapy for depression: Therapeutic mechanisms and future perspective. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.584416"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lehnert, F., Neumann, I., Kr\u00fcger, T.H.C., and Wollmer, M.A. (2023). Botulinum toxin therapy for psychiatric disorders in clinical practice: A retrospective case study. Toxins, 15.","DOI":"10.3390\/toxins15060385"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00266-025-05411-9","article-title":"Potential role of botulinum neurotoxin type A as a supportive intervention for depressive symptoms: A systematic review","volume":"50","author":"Altamura","year":"2025","journal-title":"Aesthetic Plast. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5603\/pjnns.102672","article-title":"Does botulinum toxin type A treatment influence non motor symptoms in cervical dystonia patients? A systematic review","volume":"59","author":"Dudzic","year":"2025","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12851","DOI":"10.1038\/s41598-020-69773-7","article-title":"Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites","volume":"10","author":"Makunts","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wollmer, M.A., Magid, M., Kruger, T.H.C., and Finzi, E. (2022). Treatment of depression with botulinum toxin. Toxins, 14.","DOI":"10.3390\/toxins14060383"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Finzi, E. (2023). Botulinum Toxin Treatment for Depression: A New Paradigm for Psychiatry. Toxins, 15.","DOI":"10.3390\/toxins15050336"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.55697\/tnd.2024.18","article-title":"The wear off phenomenon of repeated botulinum toxin injection for chronic migraine treatment: A retrospective study","volume":"30","author":"Hafez","year":"2024","journal-title":"Turk. J. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"\u00d6zge, A., Baykan, B., B\u0131\u00e7ak\u00e7\u0131, \u015e., Erta\u015f, M., Atalar, A.\u00c7., G\u00fcmr\u00fc, S., and Karl\u0131, N. (2024). Revolutionizing migraine management: Advances and challenges in CGRP targeted therapies and their clinical implications. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1402569"},{"key":"ref_34","first-page":"1","article-title":"Combined prophylaxis of chronic migraine with onabotulinumtoxinA and anti CGRP antibodies","volume":"11","author":"Blazek","year":"2023","journal-title":"Ann. Head Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","article-title":"Combining treatments for migraine prophylaxis: The state of the art","volume":"25","author":"Pellesi","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Argyriou, A.A., Dermitzakis, E.V., Xiromerisiou, G., and Vikelis, M. (2022). OnabotulinumtoxinA add on to monoclonal anti CGRP antibodies in treatment refractory chronic migraine. Toxins, 14.","DOI":"10.3390\/toxins14120847"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/4\/153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:13:12Z","timestamp":1774339992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/4\/153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["toxins18040153"],"URL":"https:\/\/doi.org\/10.3390\/toxins18040153","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}